Given that our findings suggest higher CRBN expression in NECs contributes to enhanced sensitivity to GSPT1 MGDs, we next investigated whether NEC-driving factors contribute to CRBN upregulation, and the enhanced sensitivity to GSPT1 MGDs. Here, CRBN is linked to neuroendocrine carcinoma.